Evidence map›Paper›PMID 39419848›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

First-in-human study of dosimetry, safety and efficacy for [

Ruiyue Zhao, Jie Lv, Mingzhao Li, Siran Xu, Wenhua Liang, Xinqing Lin, Di Gu, Guohua Zeng, Wenbin Jin, Qingsong Yan and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ruiyue Zhao *Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
Jie Lv *Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
Mingzhao Li *Department of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510230, China.
Siran XuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
Wenhua LiangDepartment of Thoracic Oncology and Surgery, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Xinqing LinState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Di GuDepartment of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510230, China.
Guohua ZengDepartment of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510230, China.
Wenbin JinCollege of Chemistry, Beijing Normal University, Beijing, 100875, China.
Qingsong YanDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
Huizhen ZhongDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
David AlexoffFive Eleven Pharma Inc, 3700 Market St., Philadelphia, PA, 19104, USA.
Karl PloesslFive Eleven Pharma Inc, 3700 Market St., Philadelphia, PA, 19104, USA.
Lin ZhuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China. zhulin@bnu.edu.cn.
Hank F KungFive Eleven Pharma Inc, 3700 Market St., Philadelphia, PA, 19104, USA. kunghf@gmail.com.
Xinlu WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China. 71lu@163.com.ORCID 0000-0003-1997-5687

Funding

Guangdong regional joint fund 2022A1515110941Guangzhou basic and applied basic research 2023A04J1196Guangzhou basic and applied basic research 2024A03J1157Guangzhou basic and applied basic research 2024A03J1228Medical Science and Technology Research of Guangdong Province 202211195047503
6 · The paper itself

Abstract

purposeBisphosphonates are pivotal in managing bone tumors by inhibiting bone resorption. This study investigates the therapeutic potential of [

methodsTen patients (age 35 to 75) with confirmed bone metastases underwent therapy with a single dose of [

resultsSerial planar whole-body scans demonstrated rapid and substantial accumulation of [

conclusionsThis study demonstrates the safety, dosimetry, and efficacy of a single therapeutic dose of [

Indexed as

Bone NeoplasmsDiphosphonatesLutetiumRadioisotopesRadiopharmaceuticalsSafetyAdultAgedFemaleHumansMaleMiddle AgedRadiometryTissue DistributionTreatment OutcomeDiphosphonatesLutetiumLutetium-177RadioisotopesRadiopharmaceuticals177Lu-labeled bisphosphonatesBone metastasisBone pain palliationDosimetryRadioligand therapy (RLT)

Identifiers

PMID39419848

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.